Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting

MIR-CABG: A Randomized, Double-blind, Placebo-controlled, Single-Center Study to Evaluate the Impact of Mupirocin on Infection Rate Post Coronary Artery Bypass Grafting

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01949935

Acronym

MIR-CABG

Enrollment

974

Registered

2013-09-25

Start date

2009-03-31

Completion date

2013-05-31

Last updated

2013-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Site Infections

Keywords

Mupirocin, Surgical Site Infections, Coronary Artery Bypass Grafting

Brief summary

The hypothesis is that application of Mupirocin to the nose before and after coronary artery bypass grafting surgery will reduce the incidence of surgical site infections.

Detailed description

Mupirocin applied to the nares is effective in eradicating nasal carriage of Staphylococcus species. Abundant evidence has documented that a majority of gram positive surgical site infections share bacterial phenotypes identical with nasal phage types. Conflicting literature exists regarding the efficacy of mupirocin in reducing the incidence of surgical site infections. A randomized prospective double-blind placebo-controlled trial is needed to help settle this question in the setting of coronary artery bypass grafting surgery where surgical site infections carry significant morbidity, cost, and mortality.

Interventions

DRUGMupirocin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults \>18 years old undergoing Coronary Artery Bypass Grafting Surgery (CABG) with or without concomitant cardiac valve surgery or other cardiac surgery, * Median sternotomy wound * Capable of informed consent

Exclusion criteria

* Allergy to mupirocin or components * Pregnant or lactating females * Emergency surgery * Pre-existing ongoing infection

Design outcomes

Primary

Measure	Time frame	Description
Surgical Site Infection	<30 days post operation	Surgical site infections (SSI) are classified as superficial, deep, or organ surgical site infections based on CDC definition.

Secondary

Measure	Time frame	Description
Mortality	< or = 30 days post operation	—
Serious adverse durg effects	< or = 30 day post operation	Rashes, rhinorrhea, pruritis, bleeding from nares
S. aureus carrier status	< or = 30 day post operation	Nasal carriage of Staphylococcus aureus assess pre-intervention and post-intervention.

Other

Measure	Time frame	Description
Incidence of subtypes of surgical site infections.	< or = 30 days post operation.	Subtypes include deep sternal wound, mediastinitis, leg saphenous vein harvest site infections.
Incidence of pneumonia	< or = 30 days post operation.	As diagnosed by sputum, radiographic, and clinical means.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026